This site is intended for healthcare professionals
News

Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial,- Novo Nordisk

Read time: 1 mins
Last updated:18th Nov 2020
Published:18th Nov 2020
Condition: Diabetes Type 2
Type: drug
Register free for full access to medthority.com